Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson. Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs ...

RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination ...

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...

Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Nivolumab plus relatlimab ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 2/3 RELATIVITY-047 trial, which showed that the fixed-dose combination of relatlimab, a LAG-3 ...

Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.

For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a "game changer that we have been waiting 10 years for," Hussein Tawbi, MD, PhD, University of Texas MD ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that primary endpoint was met in the phase II/III Relativity-047 study, a trial evaluating a fixed dose combination of company's anti-LAG-3 ...

A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial ...

Please provide your email address to receive an email when new articles are posted on . Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with ...

Please provide your email address to receive an email when new articles are posted on . The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with ...